摘要
目的 了解术后辅助内分泌治疗乳腺癌患者服药依从性现状,分析其相关危险因素.方法 选取在上海市某三级医院被确诊乳腺癌并需要接受术后辅助内分泌治疗的274例患者,通过门诊电子病历系统,回顾性分析2006～2012年所有内分泌医嘱记录,计算药物占有比（MPR）.采用Logistic回归分析治疗第1年服药依从性不良的危险因素.结果 274例乳腺癌患者术后辅助内分泌治疗期间第1～5年的总体MPR平均值分别为91％、84％、85％、83％和71％；在治疗第1年,未化疗患者以及服用他莫昔芬的患者发生服药依从性不良的风险更高.结论 乳腺癌患者术后辅助内分泌治疗期间,治疗第5年总体服药依从性不良.在内分泌治疗的第1年,需要重点关注服用他莫昔芬以及未化疗的乳腺癌患者.
Objective To investigate adherence to adjuvant hormonal therapy in breast cancer patients and to explore risk factors of non-adherence.Methods A total of 274 women diagnosed with breast cancer were chosen from a tertiary hospital in Shanghai and they received adjuvant hormonal therapy after surgery.Their hormonal therapy prescriptions and dates of refill from 2006 to 2012were obtained from the computerized outpatient record system to calculate the Medication Possession Ratio （MPR）.Predictors of non-adherence in the first year of therapy were identified by using logistic regression analysis.Results The mean MPR in breast cancer patients in 5-year adjuvant hormonal therapy were 91％ in 1st year,84％ in 2nd year,85％ in 3rd year,83％ in 4th year,and 71％ in 5th year.Patients receiving a tamoxifen prescription or no chemotherapy were prone to non-adherence to the therapy in the first year.Conclsion Adherence to adjuvant hormonal therapy in the fifth year in breast cancer patients is poor.Attention should be paid to those receiving a tamoxifen prescription or no chemotherapy in the first year of treatment.
基金
复旦大学护理科研项目(FNSF201102)
关键词
乳腺癌
内分泌治疗
服药依从性
breast cancer
hormonal therapy
adherence to medication
